The Morning Filter cover image

3 Stocks to Sell and 3 Stocks to Buy Instead

The Morning Filter

00:00

Assessing Novo Nordisk's Performance and Future Potential

This chapter reviews Novo Nordisk's disappointing first quarter results, particularly due to lower sales of the obesity drug Wegovi amid rising competition. It also discusses optimistic sales recovery prospects, a new partnership with CVS, and potential future developments in GLP-1 drugs.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app